Truist initiated coverage of Chemours with a rating of Buy and set a new price target of $27.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/27/2025 | $19.00 | Neutral → Outperform | Mizuho |
| 1/28/2025 | $27.00 | Buy | Truist |
| 7/9/2024 | $28.00 → $30.00 | Neutral → Buy | UBS |
| 6/7/2024 | $25.00 | Neutral | Mizuho |
| 4/9/2024 | $19.00 → $34.00 | Underperform → Outperform | BMO Capital Markets |
| 3/5/2024 | $37.00 → $21.00 | Buy → Neutral | UBS |
| 2/29/2024 | $45.00 → $19.00 | Outperform → Underperform | BMO Capital Markets |
| 12/1/2023 | $28.00 → $40.00 | Sector Perform → Outperform | RBC Capital Mkts |
4 - Chemours Co (0001627223) (Issuer)
4 - Chemours Co (0001627223) (Issuer)
Mizuho upgraded Chemours from Neutral to Outperform and set a new price target of $19.00
Truist initiated coverage of Chemours with a rating of Buy and set a new price target of $27.00
UBS upgraded Chemours from Neutral to Buy and set a new price target of $30.00 from $28.00 previously
SCHEDULE 13G - Chemours Co (0001627223) (Subject)
SCHEDULE 13G/A - Chemours Co (0001627223) (Subject)
SD - Chemours Co (0001627223) (Filer)